IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis
The role of proinflammatory IL-17 cytokine was studied in postmenopausal bone loss between 31 osteopenic and 41 osteoporotic women. The effect of serum IL-17A, soluble receptor activator of NF-κB (sRANK) ligand, and osteoprotegerin (OPG) levels on lumbar bone mineral densities was measured. The results demonstrated an increased IL-17A-mediated sRANK ligand elevation in postmenopausal osteoporotic bone loss.
IL-17 proinflammatory cytokine is a new inducer of bone loss. Postmenopausal osteoporosis represents a cross talk between estrogen deprivation and increased immune reactivity. The role of IL-17 was studied in the bone loss of postmenopausal osteoporosis.
Serum IL-17A, sRANK ligand, and OPG levels were investigated on bone mineral densities (BMDs) in the total lumbar (L1–L4) region in 18 pre- and 72 postmenopausal women. IL-17A, sRANK ligand, OPG levels, and BMDs were measured with enzyme-linked immunosorbent assay (ELISA) and dual-energy X-ray absorptiometry (DXA).
Increased serum IL-17A, sRANK ligand, and OPG levels were demonstrated in postmenopausal osteoporotic women compared to osteopenic women (3.65 ± 0.61 vs 3.31 ± 0.43 ng/ml for IL-17A, P < 0.007; 2.88 ± 0.84 vs 2.49 ± 0.61 ng/ml for sRANK ligand, P < 0.027; and 1.43 ± 0.07 vs 1.39 ± 0.07 ng/ml for OPG, P < 0.038). In postmenopausal women, IL-17A levels correlated inversely with total lumbar BMDs (P < 0.008, r = −0.279) and positively with sRANK ligand levels (P < 0.0001, r = 0.387) or the ratio of sRANK ligand and OPG (P < 0.013, r = 0.261), but did not with OPG levels alone.
Increased IL-17A levels are involved in postmenopausal osteoporosis, playing a role in the bone-resorpting processes.
KeywordsBone mineral density Interleukin-17 Osteoporosis Postmenopause sRANK ligand
Conflicts of interest
- 3.Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pachrco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P (2009) RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison anti-TNFα or anti-IL-1 therapies. Arthritis & Therapy. doi: 10.1186/ ar2879 Google Scholar
- 7.Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim HJ, Saito S, Nishikawa T, Takahashi N, Togari A, TomatsuT ST, Kamatani N (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes. Arthritis & Rheumatism 44:1003–1012CrossRefGoogle Scholar
- 11.Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682PubMedCentralPubMedCrossRefGoogle Scholar
- 17.Molnár I, Bohaty I, Somogyiné-Vári É (2014) A high prevalence of increased IL-17A serum levels in postmenopausal estrogen deficiency. Menopause. doi: 10.1097/GME.0000000000000125